Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics

References

• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):1–12.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a european consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Bagel J. Treat to target in psoriasis: a RealWorld experience with biologics and adjunctive topical therapy. J Drugs Dermatol. 2018;17:918.
   PubMed Web of Science ®Google Scholar
• Paul C, Gallini A, Archier E, et al. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):1–10.
   PubMedGoogle Scholar
• Fenton C, Plosker GL. Calcipotriol/betamethasone dipropionate. Am J Clin Dermatol. 2004;5(6):463–478.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Van De Kerkhof P. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp. J Eur Acad Dermatol Venereol. 2014;28(Suppl 2):10–21.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–470.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. S3 - Guidelines on the treatment of psoriasis vulgaris (english version). update. J Dtsch Dermatol Ges. 2012;10(Suppl 2): s 1–95.
   Google Scholar
• Lovato P, Norsgaard H, Tokura Y, et al. Calcipotriol and betamethasone dipropionate exert additive inhibitory efects on the cytokine expression of infammatory dendritic cell-T17 cell axis in psoriasis. J Dermatol Sci. 2016;81(3):153–164.
   PubMed Web of Science ®Google Scholar
• Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;(3):CD005028.
   PubMed Web of Science ®Google Scholar
• Vakirlis E, Kastanis A, Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag. 2008;4(1):141–148.
   PubMedGoogle Scholar
• Stein Gold LF. Topical therapies for psoriasis: improving management strategies and patient adherence. Semin Cutan Med Surg. 2016;35: s 36–44;quiz S45.
   Web of Science ®Google Scholar
• Lequang JA. Updates in psoriasis management: based on selected presentations from maui derm 2020, january 25-29, 2020, maui, Hawaii. J Clin Aesthet Dermatol. 2020;13: s 1–S17.
   Google Scholar
• Saraceno R, Andreassi L, Ayala F. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (dovobet) versus calcipotriol (daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat. 2007;18:36l–365.
   Web of Science ®Google Scholar
• Wang B, Liu W, Sun L, et al. Sequential use of calcipotriol betamethasone cream and calcipotriol ointment for psoriasis. J Clin Dermatol. 2017;46:353–355.
   Google Scholar
• Thongboonkerd V. Proteomics. Forum Nutr. 2007;60:80–90.
   PubMedGoogle Scholar
• Meng X, Jingwen D, Kaikun X, et al. In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional chinese medicine. Theranostics. 2019;9:2475–2488.
   PubMed Web of Science ®Google Scholar
• Liebermeister W, Noor E, Flamholz A, et al. Visual account of protein investment in cellular functions. Proc Natl Acad Sci U S A. 2014;111(23):8488–8493. doi: 10.1073/pnas.1314810111.
   PubMed Web of Science ®Google Scholar
• Kolbinger F, Loesche C, Valentin MA, et al. beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139(3):923–932.e8.
   PubMed Web of Science ®Google Scholar
• Amy CF, David SW, Daniel FC, et al. A framework for Multi-Omic prediction of treatment response to biologic therapy for psoriasis. J Invest Dermatol. 2019;139:100–107.
   PubMed Web of Science ®Google Scholar
• Amit KS, Tara CY, Harvinder KK, et al. Insights into interplay of immunopathophysiological events and molecular mechanistic Cascades in psoriasis and its associated comorbidities. J Autoimmun. 2021;118:102614.
   PubMed Web of Science ®Google Scholar
• Peter G, Ninette G, Katrine P, et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev. 2016;274:74–97.
   PubMed Web of Science ®Google Scholar
• Jenny G, Marc AJS, Martijn BAVD, et al. Complement activation in inflammatory skin diseases. Front Immunol. 2018;9:639.
   PubMed Web of Science ®Google Scholar
• Troldborg A, Thiel S, Jensen L, et al. Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus. Clin Exp Immunol. 2015;182(2):132–138.
   PubMed Web of Science ®Google Scholar
• Vanhoutteghem A, Djian P. Basonuclins 1 and 2, whose genes share a common origin, are proteins with widely different properties and functions. Proc Natl Acad Sci U S A. 2006;103(33):12423–12428.
   PubMed Web of Science ®Google Scholar
• Rasmus P, Rasmus KJ, Emil CP, et al. ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism. Sci Adv. 2021;7(2):eaba7381.
   PubMed Web of Science ®Google Scholar
• Zhuoshuai L, Lingfeng P, Jikang S, et al. C1QA, C1QB, and GZMB are novel prognostic biomarkers of skin cutaneous melanoma relating tumor microenvironment. Sci Rep. 2022;12(1):20460.
   PubMed Web of Science ®Google Scholar
• Reham H, Mervat H, Asmaa ME, et al. Immunoregulatory complement receptor-1 and leukocyte-associated Ig-like receptor-1 expression on leukocytes in Psoriasis vulgaris.
   Google Scholar
• Kin KC, Hill D, Feldman SR. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Expert Rev Clin Pharmacol. 2016;9(6):789–797.
   PubMed Web of Science ®Google Scholar
• Dyring-Andersen B, Bonefeld CM, Bzorek M, et al. The vitamin D analogue calcipotriol reduces the frequency of CD8+ IL-17+ T cells in psoriasis lesions. Scand J Immunol. 2015;82(1):84–91.
   PubMed Web of Science ®Google Scholar
• Haussler MR, Whitfield GK, Kaneko I, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013;92(2):77–98.
   PubMed Web of Science ®Google Scholar
• Kao JS, Fluhr JW, Man MQ, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120(3):456–464.
   PubMed Web of Science ®Google Scholar
• Sheu HM, Tai CL, Kuo KW, et al. Modulation of epidermal terminal differentiation in patients after long-term topical corticosteroids. J Dermatol. 1991;18(8):454–464.
   PubMedGoogle Scholar
• Orgaz-Molina J, Magro-Checa C, Rosales-Alexander JL, et al. Association of 25-hydroxyvitamin D serum levels and metabolic parameters in psoriatic patients with and without arthritis. J Am Acad Dermatol. 2013;69(6):938–946.
   PubMed Web of Science ®Google Scholar
• Hong SP, Oh Y, Jung M, et al. Topical calcitriol restores the impairment of epidermal permeability and antimicrobial barriers induced by corticosteroids. Br J Dermatol. 2010;162(6):1251–1260.
   PubMed Web of Science ®Google Scholar